Literature DB >> 26233637

Copeptin: Pathophysiology and potential clinical impact.

Ewelina Łukaszyk1, Jolanta Małyszko2.   

Abstract

Copeptin, a C-terminal part of the precursor pre-provasopressin is a novel biomarker of arginine-vasopressin (AVP) system. Measurements of AVP concentration are not used in clinical practice because of technical difficulties. Copeptin is synthesized in stoichiometric ratio with AVP, hence it reflects vasopressin concentration in human plasma and serum. This review outlines current research concerning the role of copeptin as a prognostic marker in different diseases and its potential clinical value.
Copyright © 2015 Medical University of Bialystok. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Chronic heart failure; Chronic kidney disease; Copeptin; Vasopressin

Mesh：

Substances：

Year:  2015        PMID： 26233637     DOI： 10.1016/j.advms.2015.07.002

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN： 1896-1126            Impact factor:   3.287


  8 in total

Review 1.  The role of copeptin in kidney disease.

Authors:  Pedro Iglesias; Ramona A Silvestre; María José Fernández-Reyes; Juan J Díez
Journal:  Endocrine       Date:  2022-10-15       Impact factor: 3.925

Review 2.  Recent advances in managing and understanding enuresis.

Authors:  Charlotte Van Herzeele; Johan Vande Walle; Karlien Dhondt; Kristian Vinter Juul
Journal:  F1000Res       Date:  2017-10-24

3.  The Effect of Renal Function and Hemodialysis Treatment on Plasma Vasopressin and Copeptin Levels.

Authors:  Esmée M Ettema; Judith Heida; Niek F Casteleijn; Lianne Boesten; Ralf Westerhuis; Carlo A J M Gaillard; Ron T Gansevoort; Casper F M Franssen; Debbie Zittema
Journal:  Kidney Int Rep       Date:  2017-01-23

4.  Copeptin levels and blood lipid profile in borderline patients with or without self-mutilation.

Authors:  Sevda Korkmaz; Bilal Üstündağ; Ömer Özer; Gülay Taşç; Şüheda Kaya; Metin Ateşçelik; Murad Atmaca
Journal:  S Afr J Psychiatr       Date:  2016-10-24       Impact factor: 1.550

5.  Copeptin in anorexia nervosa.

Authors:  Jens P Goetze; René Klinkby Støving
Journal:  Brain Behav       Date:  2020-02-19       Impact factor: 2.708

6.  Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis.

Authors:  I Wojsyk-Banaszak; P Sobkowiak; K Jończyk-Potoczna; B Narożna; W Langwiński; M Szczepanik; Z Kycler; A Bręborowicz; A Szczepankiewicz
Journal:  Mediators Inflamm       Date:  2019-10-16       Impact factor: 4.711

7.  Association of Serum Copeptin Levels with Patency of Infarct-Related Arteries in Patients with ST-Segment Elevation Myocardial Infarction.

Authors:  Birsen Doganay; Sercan Okutucu; Mustafa Cetin; Emrullah Kızıltunc; Orhan Karayigit; Can Ozkan; Muhammed Fevzi Kılınckaya; Ender Ornek
Journal:  Acta Cardiol Sin       Date:  2019-07       Impact factor: 2.672

8.  Copeptin levels predict left ventricular systolic function in STEMI patients: A 2D speckle tracking echocardiography-based prospective observational study.

Authors:  Hilal Erken Pamukcu; Mehmet Ali Felekoğlu; Engin Algül; Haluk Furkan Şahan; Faruk Aydinyilmaz; İlkin Guliyev; Saadet Demirtaş İnci; Nail Burak Özbeyaz; Ali Nallbani
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.